Company* (Symbol) |
Product |
Description |
Indication |
Status (Date)** |
CANCER | ||||
Aastrom Biosciences Inc. (ASTM) |
Aastrom Replicell Cell Production System |
Automated clinical system designed to produce patient-specific cells for treatment of various diseases |
Stem-cell therapy for patients with breast cancer |
Results from Phase II trial published in 3/15/00 issue of Blood (3/15) |
AltaRex Corp. (Canada; TSE:AXO) |
BrevaRex MAb |
Murine monoclonal antibody against the MUC1 cancer antigen |
MUC1-positive cancer |
Reported preliminary Phase I results (3/20) |
AltaRex Corp. (Canada; TSE:AXO) |
OvaRex MAb |
Modified murine monoclonal antibody that binds to CA125 cancer antigen |
Ovarian cancer |
Company reported results for first patient tested for immune response in open-label Phase II trial (3/7) |
Amgen Inc. (AMGN) |
SD-01 |
Sustained duration form granulocyte-colony stimulating factor; consists of the G-CSF protein binded to polyethylene glycol |
Chemotherapy-induced neutropenia in breast cancer patients |
Drug Royalty Corp. Inc. (TSE:DRI) described Amgen's Phase II results (3/21) |
Antigenics Inc. (AGEN) |
Oncophage |
Cancer vaccine consisting of purified, patient-specific heat shock protein-peptide complexes |
Non-Hodgkin's lymphoma |
Initiated Phase II trial (3/20) |
Aronex Pharmaceuticals Inc. (ARNX) |
Annamycin |
Liposomal anthracycline |
Refractory breast cancer |
Initiated Phase II trial (3/28) |
Avax Technologies Inc. (AVXT) |
M-Vax |
Therapeutic vaccine; tumor cells removed from patient, modified with hapten (DNP; dinitrophenyl), then injected back into patient (along with cyclophosphamide) |
Metastatic melanoma (Stage III) |
Reported interim results from low-dose Phase II trial (3/15) |
Avax Technologies Inc. (AVXT) |
M-Vax |
Therapeutic vaccine; tumor cells removed from patient, modified with hapten (DNP; dinitrophenyl), then injected back into patient (along with cyclophosphamide) |
Metastatic melanoma (Stage IV) |
Initiated Phase II trial (3/28) |
Biomira Inc. (Canada; BIOM) |
BLP25 |
Vaccine incorporates a synthetic 25-amino-acid sequence of the MUC1 cancer mucin encapsulated in a synthetic liposomal delivery system |
Non-small-cell lung cancer |
Presented immune-response data gathered in Phase II trial at the Biotechnology Industry Organization meeting in Boston (3/27) |
Cell Pathways Inc. (CLPA) |
Aptosyn |
Exisulind; orally active drug designed to induce apoptosis in precancerous cells; inhibits a cyclic GMP phospho-diesterase |
Children with familial adenomatous polyposis |
Completed enrollment in open-label Phase II trial (3/29) |
Eligix Inc.* |
HDM (High Density Microparticle) technology |
Use of high-density micro-particles coated with a monoclonal antibody specific to CD8+ cells to selectively deplete CD8+ lymphocytes from donor lymphocyte infusions after relapse of hematologic malignancies |
Protection from from graft-vs.-host disease in patients receiving donor lymphocyte infusions to achieve remission |
Reported results of Phase I/II trial at the European Bone Marrow Transplant Meeting in Innsbruck, Austria (3/16) |
EntreMed Inc. (ENMD) |
-- |
2-mehtoxyestradiol; small-molecule, orally active angiogenesis inhibitor |
Advanced breast cancer |
Initiated Phase I trial (3/31) |
FeRx Inc.* |
MTC-DOX |
Sustained-release formulation of doxorubicin delivered via magnetic targeted carriers (micro-particles, composed of elemental iron and activated carbon) |
Primary liver cancer |
Reported data from Phase I/II trial (3/27) |
Genta Inc. (GNTA) |
G3139 |
Antisense compound; synthetic DNA strands that bind to mRNA for the bcl2 gene (proto-oncogene) |
Advanced malignant melanoma |
Initiated pivotal study of G3139 in combination with dacarbazine (3/9) |
IBC Pharmaceuticals LLC (joint venture between Immunomedics Inc. [IMMU] and Beckman Coulter Corp. [NYSE:BEC]) |
Pentacea |
Bispecific antibody delivered via injection; one arm (injected first) binds to CEA+ tumors; radiation carrier arm is subsequently injected |
Solid tumors |
Initiated Phase I/II trial (3/1) |
Ilex Oncology Inc. (ILXO) |
ILX23-7553 |
Vitamin D3 analogue |
Refractory solid tumors |
Initiated a second Phase I trial using the drug alone and in combination with dexamethasone (3/21) |
The Immune Response Corp. (IMNR) |
-- |
Cancer vaccine utilizing a fibroblast cell line (genetically modified to secrete granulocyte macrophage colony-stimulating factor) mixed with irradiated tumor (glioma) cell lines to seek to boost antitumor immune response |
Prevention of brain tumor recurrence |
Initiated Phase I trial (3/8) |
Immunomedics Inc. (IMMU) |
|
Use of ex vivo genetic engineering of T lymphocytes involving insertion of gene controlling the binding region of humanized antibody against carcinoembryonic antigen |
Colorectal cancer |
Initiated Phase I trial (3/2) |
Introgen Therapeutics Inc.* and Aventis Pharmaceuticals (unit of Aventis SA [NYSE:AVE]) |
|
Intratumoral delivery of p53 gene via adenoviral vector |
Head and neck cancer |
The Recombinant DNA Advisory Committee of the National Institutes of Health cleared Phase III protocol (3/10) |
Ligand Pharmaceuticals Inc. (LGND) |
Targretin capsules (FDA-approved) |
Bexarotene; synthetic retinoid analogue that selectively activates retinoid X receptors; oral |
Refractory cutaneous T-cell lymphoma |
Presented data from two Phase II/III trials in posters at the American Academy of Dermatology's 58th Annual Meeting in San Francisco (3/13) |
Matrix Pharmaceutical Inc. (MATX) |
FMdC |
Nucleoside analogue believed to inhibit DNA synthesis directly by incorporation into DNA strands and indirectly by blocking the action ribonucleotide reductase, an enzyme important to nucleotide formation; structure and action similar to gemcitabine |
Cancer |
Initiated two combination therapy trials, one with cisplatin and one with 5-fluorouracil (3/22) |
NeoPharm Inc. (AMEX:NEO) and Pharmacia & Upjohn (NYSE:PNU) |
|
Liposomal-encapsulated formulation of paclitaxel |
Cancer |
Completed Phase I studies (3/15) |
NeoRx Corp. (NERX) |
Skeletal Targeted Radiotherapy |
Small-molecule carrier of the radionuclide holmium-166, designed to deliver radiation therapy selectively to bone, and especially those areas of bone undergoing increased metabolism |
Ewing's sarcoma |
Initiated clinical trial (3/24) |
Procept Inc. (subsidiary of HeavenlyDoor.com Inc.; HVDC) |
|
06-Benzylguanine (BG); chemosensitzing agent designed to overcome tumor resistance to 06-alkylating agents; BG inactivates AGT, a DNA repair protein |
Advanced soft tissue sarcoma |
Initiated Phase II trial sponsored by the National Cancer Institute (3/22) |
Sepracor Inc. (SEPR) |
|
(S) doxazosin; single-isomer form of Pfizer Inc.'s (NYSE:PFE) Cardura |
Benign prostatic hyperplasia |
Initiated Phase I trial (3/13) |
SuperGen Inc. (SUPG) |
|
Decitabine; inhibits DNA methyltransferase activity |
Non-small-cell lung cancer |
Presented data from Phase I trial at the 10th International Congress on Anticancer Treatment (3/2) |
SuperGen Inc. (SUPG) |
|
Decitabine; inhibits DNA methyltransferase activity |
Myelodysplastic syndrome |
Results from Phase II study were published in the 3/00 issue of the Journal of Clinical Oncology (3/15) |
Techniclone Inc. (TCLN) |
Oncolym |
LYM-1 murine monoclonal antibody to HLA-DR10 protein (cell surface marker present on 80% of lymphoma cells), labeled with I-131 |
Non-Hodgkin's B cell lymphoma |
Techniclone clarified Oncolym's clinical status in response to media reports; partner Schering AG (Germany) is shifting to a higher, single-dose regimen for future trials in place of the previous three-dose regimen; new Phase I/II slated for second quarter (3/20) |
Vion Pharmaceuticals Inc. (VION) |
Tapet |
Tumor amplified protein expression therapy; Salmonella vector consisting of highly attenuated bacteria that preferentially replicate in tumors |
Advanced, refractory cancers |
Received approval to begin Phase I trial at the National Cancer Institute (3/28) |
Vion Pharmaceuticals Inc. (VION) |
Triapine |
Ribonucleotide reductase inhibitor that blocks a crucial step in the synthesis of DNA |
Cancer |
Completed Phase I trial (3/2) |
Xenova Group plc (UK; XNVA) |
XR9576 |
P-glycoprotein pump that restores the sensitivity of multidrug-resistant cancer cells to specific cytotoxic drugs |
Ovarian cancer |
Reported results of Phase IIa trial of XR9576 and paclitaxel; announced Phase III trials would begin later this year (3/7) |
CARDIOVASCULAR | ||||
Avant Immunotherapeutics Inc. (AVAN) |
TP10 |
Soluble form of complement receptor 1 (CR1), designed to inhibit complement proteins |
Infants undergoing cardiac surgery |
Reported results of Phase I/II trial (3/27) |
AVI BioPharma Inc. AVII) |
Resten-NG |
Synthetic polymer antisense compound targeting c-myc oncogene, which has been implicated in cell proliferation |
Prevention of restenosis |
Completed Phase I trial and initiated Phase II trial (3/16) |
Avigen Inc. (AVGN) |
Coagulin-B |
Factor IX gene therapy delivered via adeno-associated viral vector; injected into the thigh |
Hemophilia B |
Data from Phase I trial at Stanford University and Children's Hospital of Philadelphia was published in 3/00 issue of Nature Genetics (3/1) |
Chiron Corp. (CHIR) |
|
Recombinant fibroblast growth factor-2 (FGF-2) |
Symptomatic coronary artery disease patients who are not candidates for angioplasty or bypass surgery |
Phase II trial failed to achieve primary endpoint of statistically significant improvement in exercise testing at 90 days; positive trends were observed in angina reduction in the trial, dubbed FIRST (FGF-2 Initiating Revascularization Support Trial) (3/12) |
Collateral Therapeutics Inc. (CLTX), Schering AG (Germany), and Berlex Laboratories (subisidiary of Schering) |
Generx (Ad5FGF4) |
Angiogenic gene therapy; the fibroblast growth factor-4 gene (FGF-4) is delivered to the heart via an adenoviral vector during a diagnostic angiogram |
Stable exertional angina due to coronary artery disease |
Reported preliminary results from Phase I/II trial, dubbed AGENT (Angiogenic GENe Therapy) (3/20) |
Connetics Corp. (CNCT) |
ConXn |
Recombinant form of human relaxin H2 |
Peripheral vascular disease |
Announced plan to expand clinical testing program into new indication with request for regulatory approval of Phase II trial (3/9) |
COR Therapeutics Inc. (CORR) and Schering-Plough Corp. (NYSE: SGP) |
Integrilin (FDA-approved) |
Eptifibatide; small-molecule compound (derived from rattlesnake venom) that inhibits GPIIb/IIIa receptor, which mediates platelet aggregation |
Non-urgent balloon angioplasty combined with intracoronary stenting |
Reported final results for the primary endpoint of ESPRIT (Enhanced Suppression of Platelet Receptor GPIIb-IIIa Using Integrilin Therapy) trial at the American College of Cardiology's (ACC) 49th Annual Meeting (3/14) |
CV Therapeutics Inc. (CVTX) |
CVT-510 |
Selective adenosine A1 receptor antagonist |
Atrial arrhythmias |
Presented Phase I trial results at the ACC meeting (3/14) |
CV Therapeutics Inc. (CVTX) |
CVT-510 |
Selective adenosine A1 receptor antagonist |
Atrial fibrillation |
Initiated second Phase II trial (3/22) |
CV Therapeutics Inc. (CVTX) |
Ranolazine |
Piperazine acetamide |
Chronic angina |
Presented positive Phase III trial data at the ACC meeting (3/15) |
CytRx Corp. (CYTR) |
Flocor |
Purified poloxamer 188; surfactant molecule that alters the way cells and molecules interact with water |
Sickle cell disease |
Company conducted additional analysis of data from Phase III trial, in which Flocor failed to meet primary efficacy endpoint of decreasing length of sickle cell anemia-associated vascular occlusive crisis (12/99); CytRx intends to proceed with development and conduct an additional trial (3/14) |
Elanex Pharma Group* |
Epomax |
Recombinant erythropoietin; Elanex said product differs from Amgen's (AMGN) by using shorter APA1 DNA fragment and BHK host hells; company claims its version of EPO can be administered in lower doses |
Hemodialysis |
Released dosing information from clinical trial (3/20) |
Immunex Corp. (IMNX) |
Enbrel (FDA-approved) |
Recombinant, soluble T75 tumor necrosis factor receptor (TNFr) linked to the Fc portion of human IgG1 |
Advanced heart failure |
Reported trial data at the ACC meeting (3/15) |
Genentech Inc. (NYSE: DNA) |
TNKase |
Tenecteplase; second-generation recombinant plasminogen activator with greater specificity to fibrin than Genentech's first-generation tissue-plasminogen activator (Activase) |
Acute myocardial infarction |
Announced plan for four clinical trials of TNKase in combination with various antithrombotic agents; trials will enroll a total of 9,000 patients; the ASSENT (ASsessment of the Safety and Efficacy of New Thrombolytic Regimens) is the largest of the trials and will enroll 6,000 patients in three treatment arms: tenecteplase and heparin sodium; tenecteplase and enoxaparin sodium (low-molecular-weight heparin); and a half dose of tenecteplase combined with a low dose of heparin sodium and abciximab (ReoPro, developed by Johnson & Johnson subsidiary Centocor Inc.; NYSE:JNJ) (3/13) |
Texas Biotechnology Corp. (AMEX:TXB) and SmithKline Beecham plc (UK;NYSE:SBH) |
Novastan Injection |
Synthetic small molecule (argotroban) derived from arginine; acts as a direct inhibitor of thrombin |
Anticoagulant therapy for patients with heparin-induced thrombocytopenia |
Presented positive Phase III trial results at the ACC meeting (3/13) |
United Therapeutics Corp. (UTHR) |
Uniprost |
Structural analogue of prostacylcin |
Pulmonary hypertension |
Reported positive preliminary results from pivotal trial (3/27) |
CENTRAL NERVOUS SYSTEM | ||||
Axonyx Inc. (OTC BB:AXYX) |
Phenserine |
Brain-targeted, reversible inhibitor of acetylcho-linesterase enzyme |
Alzheimer's disease |
Reported results from Phase I trial (3/28) |
Boston Life Sciences Inc. (BLSI) |
Altropane |
Radioimaging probe for dopamine neurons |
Diagnosis of early Parkinson's disease |
Completed enrollment in Phase III trial (3/15) |
NeoTherapeutics Inc. (NEOT) |
Neotrofin (AIT-082) |
Small-molecule compound designed to cross blood-brain barrier and enhance nerve cell function by increasing levels of neurotrophic factors |
Alzheimer's disease |
Initiated Phase II/III trial (3/29) |
Neurocrine Biosciences Inc. (NBIX) |
NBI-34060 |
Type 1 GABA-a receptor agonist; chemically distinct from benzodiazepines |
Insomnia |
Initiated first of 14 trials slated for 2000 (3/8) |
Pharmos Corp. (PARS) |
Dexanabinol |
Non-psychotropic synthetic analogue of marijuana (intravenous) |
Traumatic brain injury |
Completed third cohort of Phase II trial (3/7) |
Repligen Corp. (RGEN) |
|
Secretin hormone |
Autism in children |
Initiated Phase II trial (3/29) |
INFECTION | ||||
Amerimmune Pharmaceuticals Inc. (OTC BB: AMUN) |
Cytolin |
Monoclonal antibody that blocks certain adhesion molecules on killer T cells |
HIV infection |
Initiated Phase I/II trial (3/6) |
Cangene Corp. (Canada; TSE:CNJ) |
|
Anti-hepatitis B hyperimmune product |
Hepatitis B infection |
Initiated pivotal trial (3/17) |
Cubist Pharmaceuticals Inc. (CBST) |
Daptomycin |
Lipopeptide antibiotic (intravenous) |
Serious and life-threatening grampositive bacterial infections |
Presented data from two Phase II trials at the Centers for Disease Control's 4th Decennial Conference on Nosocomial and Healthcare-Associated Infections in Atlanta (3/6) |
Enzo Biochem Inc. (NYSE:ENZ) |
EHT899 |
Immune modulation treatment that involves oral administration of specific hepatitis B proteins to control the antiviral immune response |
Chronic hepatitis B virus infections |
Announced preliminary results of Phase I trial (3/28) |
ImmuCell Corp. (ICCC) |
DiffGAM |
Bovine anti-Clostridium difficile immunoglobulins; produced from the milk of hyperimmunized cows |
Clostridium difficile-associated diarrhea |
Reported preliminary results of open-label Phase I/II trial (3/28) |
The Immune Response Corp. (IMNR) and Agouron Pharmaceuticals Inc. (subsidiary of Warner-Lambert Co. [NYSE:WLA]) |
Remune |
Envelope-depleted, inactivated AIDS virus (emulsified with adjuvant) |
HIV-1 infection |
Presented data from open-label trial measuring immune response to Remune and highly active antiretroviral therapy (HAART) (3/6) |
Inhibitex Inc.* |
S. aureus Immune Globulin Intravenous (SA-IGIV; human) |
Antibody-based product targeting antibiotic-resistant Staphylococcus aureus; highly purified human immunoglobulin product derived from pooled adult human plasma selected for levels of antibodies specific for S. aureus |
Prevention of S. aureus infection in patients receiving hemodialysis |
Initiated Phase I/II trial (3/22) |
Isis Pharmaceuticals Inc. (ISIP) and Elan Corp. plc (NYSE:ELN) |
ISIS 14803 |
Antisense drug; 20-base phosphorothioate oligonucleotide designed to inhibit replication of hepatitis C virus |
Chronic hepatitis C |
Initiated Phase I/II trial (3/1) |
Palatin Technologies Inc (AMEX:PTN) |
LeuTech |
Radiolabeled monoclonal-antibody-based system for imaging infection (product binds specifically to white blood cells) |
Diagnosis of equivocal appendicitis |
Clinical trial results published in 3/00 issue of The Journal of Nuclear Medicine (3/23) |
Trimeris Inc. (TRMS) and Hoffmann-La Roche Inc. (Switzerland) |
T20 |
Antiviral fusion-inhibiting compound (twice-daily subcutaneous injection) |
HIV infection |
Initiated Phase II open-label trial to evaluate alternative formulations (3/14) |
MISCELLANEOUS | ||||
Alliance Pharmaceutical Corp. (ALLP) |
LiquiVent |
Perflubron; oxygen-carrying liquid that is used in partial liquid ventilation method |
Acute lung injury and acute respiratory distress syndrome |
Data Safety and Monitoring Board reviewed safety data in Phase II/III trial and recommended continuation; as a result of a separate interim analysis, the company expanded the study to include 15 additional patients for each of the three study arms (3/16) |
Amarillo Biosciences Inc. (OTC BB: AMAR) |
|
Orally administered interferon-alpha |
Fibromyalgia syndrome |
Reported data from Phase II trial (3/9) |
Anika Therapeutics Inc. (ANIK) and Zimmer Inc. (subsidiary of Bristol-Myers Squibb Co. [NYSE:BMY]) |
Orthovisc |
Ultra-pure, high-molecular-weight naturally derived hyaluronic acid (intra-articular injection) |
Osteoarthritis of the knee |
Completed Phase III trial (3/15) |
Ares-Serono Group (Switzerland) |
Rebif beta-1a |
Recombinant interferon |
Relapsing-remitting multiple sclerosis |
Reported four-year data from PRISMS (Prevention of Relapses and Disability By Interferon Beta-1a Subcutaneously in Multiple Sclerosis) trial (3/23) |
Carrington Laboratories Inc. (CARN) |
Aliminase (formerly CARN 1000) |
Oral anti-inflammatory complex carbohydrate |
Ulcerative colitis |
Discontinued development based on Phase III failure to achieve statistically significant improvement (3/24) |
Cellegy Pharmaceuticals Inc. (CLGY) |
Anogesic |
Proprietary formulation of nitroglycerin ointment |
Reduction of pain associated with anal fissures |
Initiated second Phase III trial (3/9) |
Cellegy Pharmaceuticals Inc. (CLGY) |
Tostrex |
Transdermal testosterone gel |
Male hypogonadism |
Initiated pivotal Phase III trial (3/29) |
Connetics Corp. (CNCT) |
Olux Foam |
Foam formulation of clobetasol proprionate 0.05%; super-high-potency corticosteroid |
Scalp psoriasis |
Presented positive Phase III trial data at the 58th Annual Meeting of the American Academy of Dermatology in San Francisco (3/11) |
Discovery Therapeutics Inc. (DSCO) |
SuperVent Aerosol Solution |
Tyloxapol (non-anionic alkalaryl and polyether alcohol); anti-inflammatory inhibitor of NF-(kappa)B |
Cystic fibrosis |
Reported preliminary data from Phase IIa trial (3/28) |
Dynavax Technologies Corp.* |
AIC |
Conjugate of purified ragweed allergen (Amb a 1) to an immunostimulatory polynucleotide DNA sequence |
Ragweed allergy |
Presented results of Phase I open-label trial at the 56th Annual American Academy of Allergy, Asthma and Immunology meeting in San Diego (3/8) |
Genentech Inc. (NYSE:DNA), Novartis AG (Switzerland) and Tanox Inc. (TNOX) |
|
Olizumab/rhuMAb-E25; recombinant humanized monoclonal antibody to IgE; subcutaneous |
Asthma |
Reported positive data from two Phase III trials at the 56th Annual Meeting of the American Academy of Allergy, Asthma and Immunology in San Diego (3/4) |
Genzyme Tissue Repair (GZTR) |
Carticel (FDA-approved) |
Autologous cultured chondrocytes |
Repair of damaged cartilage on the thigh-bone part of the knee |
Reported summary of the sixth report of the company's Cartilage Repair Registry at the annual meeting of the American Academy of Orthopedic Surgeons in Orlando (3/17) |
Gliatech Inc. (GLIA) |
Adcon-L (FDA-approved) |
Anti-adhesion barrier gel (semisynthetic carbohydrate polymer) |
To inhibit post-operative adhesions involving spinal cord and nerve roots, and to improve patient outcome following lumbar disc surgery |
Company provided information addressing concerns about alleged increase in cerebrospinal fluid leaks associated with the product (3/20) |
Idec Pharmaceuticals Corp. (IDPH) and Mitsubishi Chemical Corp. (Japan) |
Idec-114 |
Primatized anti-B7-1 monoclonal antibody; blocks binding of B7-1 ligand on antigen-presenting cells to CD28 receptor on T cells |
Moderate to severe psoriasis |
Reported results from Phase I trial (3/15) |
Immunex Corp. (IMNX) |
Enbrel (FDA-approved) |
Etanercept; recombinant, soluble p75 tumor necrosis factor receptor (TNFr)linked to the Fc portion of human IgG1 |
Juvenile rheumatoid arthritis |
Positive trial data published in 3/16/00 issue of The New England Journal of Medicine (3/15) |
InKine Pharmaceutical Co. Inc. (INKP) |
CBP-1011 |
Oral steroid, designed as safer alternative to prednisone |
Idiopathic thrombocytopenic purpura |
Initiated single-dose human pharmacokinetic study (3/6) |
Nortran Pharmaceuticals Inc. (Canada; CDNX:NRT) |
CP1 |
Non-narcotic cough suppressant |
Chronic idiopathic |
Initiated Phase II trial (3/28) |
Pharmadigm Inc.* |
PB005 |
Synthetic injectable dosage form of dehydroepiandosterone (DHEA) sulfate |
Severely burned patients undergoing autologous skin grafting |
Presented Phase II results at 32nd Annual Meeting of the American Burn Association in Las Vegas (3/17) |
Pharming Group NV (the Netherlands) and Genzyme General (GENZ) |
|
Transgenic recombinant human alpha-glucosidase |
Infants with Pompe's disease |
Reported Phase II results (3/15) |
QLT PhotoTherapeutics Inc. (QLTI) and CIBA Vision (eye care unit of Novartis AG; Switzerland) |
Visudyne |
Verteporfin for injection; photodynamic therapy is activated through use of specially designed laser that produces low-level, non-thermal 689-nm light |
Age-related macular degeneration |
Expanded treatment IND trial in North America to add 200 new sites (3/15); reported positive two-year results from Phase III study and one-year results from separate Phase IIIb study (3/28) |
Regeneron Pharmaceuticals Inc. (REGN) and The Procter & Gamble Co. (NYSE:PG) |
Axokine |
Second-generation ciliary neurotrophic factor |
Obesity |
Initiated Phase II trial that will not exclude patients with prior history of herpes cold sores; in Phase I trial, some patients who received higher doses who had previously contracted herpes simplex virus experienced cold sores related to HSV reactivation (3/28) |
Xoma Ltd. (XOMA) |
|
Recombinant humanized antibody against CD11a |
Prevention of rejection of kidney transplants |
Initiated Phase I/II trial of product in combination with standard immunosuppressive drugs (3/30) |
Notes: | ||||
* Indicates a privately held company | ||||
** The dates listed indicate the issue dates of press releases, and are not necessarily the dates on which stated events took place. | ||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; SBI=Stockholm Borsinformation; SSE = Swedish Stock Exchange; TSE = Toronto Stock Exchange | ||||
ND = Not disclosed | ||||
ACC = American College of Cardiology | ||||
